Les médicaments reconditionnés conservent-ils leur stabilité ?

A crucial study spearheaded by the pharmacy team at Vinatier Hospital in Lyon, France, is meticulously examining the stability of commonly prescribed psychiatric medications after they are removed from their original packaging. This pioneering research, titled "Études de Stabilité des Médicaments Reconditionnés" (ESMR), aims to provide robust scientific data to refine and adapt medication dispensing practices, thereby bolstering patient safety, improving operational efficiency, and mitigating drug waste within hospital settings.

The Evolving Landscape of Hospital Pharmacy and Automated Dispensing

The modern hospital medication circuit has undergone significant transformation, with automated nominative dispensing systems increasingly becoming a cornerstone of pharmaceutical care. This sophisticated approach involves the individualized preparation and packaging of medication doses for each patient, a process designed to enhance traceability, minimize human error, and streamline administration. At Vinatier Hospital, this critical function is performed by two advanced repackaging automatons, which systematically prepare patient-specific doses.

While the benefits of automated dispensing are undeniable – reducing medication errors, improving inventory management, and ensuring a higher degree of traceability from pharmacy to bedside – the process introduces a specific pharmaceutical challenge: the stability of drugs once they are removed from their primary, manufacturer-designed packaging. The original packaging plays a vital role in protecting pharmaceutical products from environmental factors such as light, moisture, and oxygen, which can degrade the active pharmaceutical ingredient (API) or alter the physical characteristics of the dosage form.

The act of de-packaging and subsequent repackaging, even into new unit-dose formats, exposes the medication to different environmental conditions and potentially different materials, raising questions about how long the drug maintains its chemical integrity and physical properties. This is not a trivial concern; drug degradation can lead to a reduction in therapeutic efficacy, the formation of potentially toxic by-products, or changes in dissolution rates, all of which can have serious implications for patient outcomes.

The Knowledge Gap and the Imperative for Research

Currently, comprehensive scientific data on the stability of medications after de-packaging, particularly for the vast array of drugs used in hospital pharmacopoeias, remains limited. In the absence of definitive, product-specific data, hospital pharmacists are compelled to adopt highly cautious, conservative expiration dates for repackaged medications. While this prudent approach prioritizes patient safety, it inherently leads to several operational drawbacks: increased workload for pharmacy staff due to more frequent repackaging cycles, logistical complexities in managing shorter shelf-lives, and, most significantly, a substantial amount of preventable drug waste.

The financial burden associated with medication waste in healthcare systems is considerable. A study published in the Journal of the American Medical Association (JAMA) estimated that drug waste in the U.S. healthcare system alone could amount to billions of dollars annually. For hospitals, this translates into direct financial losses and inefficient resource allocation. Beyond the economic aspect, the environmental impact of disposing of unused or expired medications also presents a growing concern.

It was precisely this recognized gap in knowledge and the associated operational and economic inefficiencies that spurred the initiation of the ESMR project. The core objective of this collaborative research is to furnish hospital pharmacy teams with robust, evidence-based scientific data on the stability of commonly used psychiatric medications after their initial packaging has been breached for automated repackaging. This data will be instrumental in enabling pharmacists to adapt and optimize dispensing practices, moving beyond overly cautious assumptions towards precisely defined, scientifically validated stability periods.

The ESMR Study: Objectives and Methodology

The ESMR study is meticulously designed to assess both the physical and chemical stability of selected psychiatric medications over an extended period. The current phase of the study focuses on several key specialties, reflecting their high usage and critical importance in psychiatric care:

1. Aripiprazole: An atypical antipsychotic widely used in the treatment of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. The study includes both classic tablets and orodispersible tablets (ODT), a formulation designed to dissolve quickly in the mouth without water, which may have different stability characteristics due to its specific excipients and rapid dissolution properties.
2. Sertraline: A selective serotonin reuptake inhibitor (SSRI) antidepressant, commonly prescribed for major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, and social anxiety disorder. The study investigates sertraline capsules.

For these medications, physical and chemical stability will be monitored over a six-month period. Physical stability assessments typically involve observing changes in appearance (color, shape, disintegration), hardness, friability, and dissolution rates. Chemical stability involves quantifying the active pharmaceutical ingredient (API) using highly precise analytical techniques to detect any degradation products or a decrease in API concentration below acceptable limits.

To accurately simulate real-world conditions encountered during automated dose preparation and subsequent storage, the medications are subjected to various controlled environmental conditions. These include conditions that mimic the automated repackaging process itself, as well as ambient storage conditions typical of a hospital ward or patient’s room. Hundreds of tablets and capsules have been allocated for these rigorous assays, underscoring the comprehensive nature of the research.

A Collaborative Endeavor Driving Pharmaceutical Innovation

The success of such a complex pharmaceutical study hinges on a multidisciplinary approach and the synergistic collaboration of specialized institutions. The ESMR project exemplifies this, bringing together the expertise of:

• The Pharmaceutical Team of Vinatier Hospital: Providing direct clinical context, identifying critical medications, and managing the practical aspects of drug handling and repackaging processes.
• The Pharmacology-Toxicology Laboratory of Hospices Civils de Lyon (HCL): Offering advanced analytical capabilities and expertise in drug quantification and degradation product identification. HCL’s laboratories are equipped with sophisticated instruments capable of measuring drug quantities with extreme precision, crucial for detecting subtle changes in chemical stability.
• The Institute of Pharmaceutical and Biological Sciences of Lyon (ISPB): Contributing fundamental knowledge in pharmaceutical sciences, including galenic formulation, drug stability principles, and analytical method development and validation.

This robust collaboration ensures that all facets of drug stability are thoroughly investigated, from macroscopic physical changes to microscopic chemical alterations, guaranteeing the scientific rigor and clinical relevance of the findings.

Building on a Proven Track Record: The Clozapine Precedent

The ESMR project is not an isolated initiative but rather an extension of successful prior research conducted at Vinatier Hospital. A foundational study focused on the stability of clozapine, another critical antipsychotic medication, after de-packaging. The results of this initial work were significant and were subsequently published in the European Journal of Hospital Pharmacy (Emonet et al., 2024), a highly respected peer-reviewed journal in the field of hospital pharmacy.

That study specifically demonstrated that clozapine 100 mg Viatris tablets maintained their physicochemical properties for a period of 12 weeks after being repackaged under the specific production conditions employed at Vinatier Hospital. This finding provided invaluable evidence, allowing the hospital to adjust its dispensing protocols for clozapine with increased confidence, thereby reducing waste and optimizing workflow without compromising patient safety. The success of the clozapine study serves as a powerful precedent, validating the methodology and reinforcing the necessity of the broader ESMR initiative.

Broader Implications for Patient Safety, Efficiency, and Cost Savings

The practical implications of the ESMR study extend far beyond the walls of Vinatier Hospital. The reliable data generated from this research is poised to have a profound impact on various aspects of pharmaceutical care:

• Enhanced Medication Safety: By providing evidence-based stability periods, the study eliminates guesswork and ensures that patients receive medications that retain their full therapeutic efficacy and are free from harmful degradation products. This directly contributes to a safer medication circuit, a paramount concern for all healthcare providers.
• Optimized Dispensing Operations: Pharmacy and nursing teams will benefit from clear, validated guidelines for the shelf-life of repackaged drugs. This facilitates more efficient planning of automated dispensing cycles, reduces the need for frequent, labor-intensive repackaging, and streamlines medication management on wards.
• Significant Cost Reduction: Extending the scientifically validated shelf-life of repackaged medications, even by a few weeks, can dramatically reduce drug waste. Considering the high cost of many psychiatric medications, this translates into substantial financial savings for healthcare institutions, allowing resources to be reallocated to other critical areas of patient care.
• Environmental Sustainability: Reducing drug waste aligns with broader environmental sustainability goals in healthcare, minimizing the disposal of pharmaceutical products into landfills or wastewater systems.
• Potential for Regulatory Influence: The robust scientific data produced by the ESMR study could inform and influence national and international regulatory guidelines pertaining to drug repackaging and stability. This could lead to the development of standardized best practices across healthcare systems, elevating the quality and safety of pharmaceutical care globally.
• Empowerment of Healthcare Professionals: Armed with precise data, pharmacists and nurses can make informed decisions regarding medication management, fostering a greater sense of confidence in their dispensing and administration practices.

The Regulatory Landscape and Pharmacovigilance

In France, the National Agency for the Safety of Medicines and Health Products (ANSM) plays a critical role in regulating drug manufacturing, distribution, and usage. Similar bodies exist across Europe (e.g., European Medicines Agency, EMA) and internationally. These agencies set stringent standards for drug stability and quality. While manufacturers provide stability data for original packaging, the post-repackaging scenario falls into a more complex grey area often managed by hospital-specific protocols based on limited data or conservative assumptions. The ESMR study directly contributes to filling this void, offering a scientific basis that aligns with the principles of good manufacturing practices (GMP) and pharmacovigilance, ensuring drug quality throughout its entire journey to the patient.

Hospital management, including Dr. Jean-Pierre Brun, Director of Pharmacy Services at a hypothetical leading French hospital, would likely underscore the strategic importance of such studies. "Our commitment to patient safety and operational excellence drives us to continually seek innovative solutions," Dr. Brun might state. "The ESMR project exemplifies this dedication, providing invaluable insights that will not only optimize our internal processes at Vinatier but also contribute significantly to the broader body of pharmaceutical knowledge, setting new benchmarks for medication management in psychiatric care."

Future Outlook and Expected Milestones

The ESMR project is progressing with clear milestones for the dissemination of its findings. The results concerning aripiprazole are anticipated to be published before the end of 2026, offering crucial insights into the stability of this widely used antipsychotic in its various formulations. Following this, the data pertaining to sertraline capsules is expected by the summer of 2027. These publications will provide the scientific community and, more importantly, hospital pharmacy practitioners with actionable, evidence-based guidance.

The success of the clozapine study and the ongoing ESMR initiative highlight a critical area of pharmaceutical research. It is plausible that these pioneering efforts will pave the way for further investigations into other drug classes, complex formulations, or specific patient populations, continuously refining medication management practices. The long-term vision articulated by the pharmacists involved, Jonathan Boisramé, Bertrand Clerc, and Hélène Maillot, is to establish a comprehensive evidence base that supports safe, efficient, and sustainable medication dispensing practices, ultimately enhancing the quality of care for patients in psychiatric settings and beyond. This commitment to scientific rigor and patient-centric innovation positions Vinatier Hospital at the forefront of pharmaceutical advancements in hospital care.